Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms

FDA staffers have expressed significant concerns about the side effects tied to Eli Lilly’s experimental rheumatoid arthritis drug baricitinib (Olumiant), which is once again up for review after the agency rejected it last year.